Sara Bringhen Selected Research

Melphalan (Alkeran)

12/2020	The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
1/2020	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
1/2020	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
1/2018	Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
11/2017	Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
3/2017	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
10/2014	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
4/2014	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
3/2014	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
3/2014	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sara Bringhen Research Topics

Disease

88	Multiple Myeloma 10/2022 - 08/2002
8	Neoplasms (Cancer) 11/2020 - 07/2010
6	Neutropenia 01/2021 - 07/2011
5	Infections 01/2021 - 06/2013
5	Peripheral Nervous System Diseases (PNS Diseases) 01/2017 - 12/2010
3	Renal Insufficiency (Renal Failure) 10/2018 - 10/2008
3	Anemia 01/2018 - 10/2008
2	Thrombocytopenia (Thrombopenia) 05/2020 - 07/2011
2	Disease Progression 10/2017 - 08/2007
2	Thromboembolism 03/2011 - 03/2006
2	Thrombosis (Thrombus) 10/2007 - 03/2006
1	Hypertension (High Blood Pressure) 01/2021
1	Residual Neoplasm 12/2020
1	Frailty 01/2020
1	Immunoglobulin Light-chain Amyloidosis 01/2018
1	Obesity 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Dyslipidemias (Dyslipidemia) 01/2018
1	Leukemia 10/2017
1	Cardiotoxicity 01/2017
1	Pneumonia (Pneumonitis) 01/2017
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2017
1	Bone Diseases (Bone Disease) 10/2015
1	Chromosome Aberrations (Chromosome Abnormalities) 09/2015
1	Pulmonary Embolism 01/2012
1	Venous Thromboembolism 01/2012
1	Sudden Death 03/2011
1	Fever (Fevers) 10/2008
1	Hypocalcemia 10/2008
1	Bone Marrow Diseases (Bone Marrow Disease) 08/2007
1	Ovarian Neoplasms (Ovarian Cancer) 07/2007
1	Pathologic Complete Response 03/2007

Drug/Important Bio-Agent (IBA)

26	Dexamethasone (Maxidex)FDA LinkGeneric 10/2022 - 01/2004
26	Thalidomide (Thalomid)FDA Link 01/2018 - 01/2004
25	Melphalan (Alkeran)FDA LinkGeneric 12/2020 - 08/2002
24	Bortezomib (Velcade)FDA Link 01/2021 - 04/2007
23	Lenalidomide (CC 5013)FDA Link 10/2022 - 07/2007
23	Prednisone (Sone)FDA LinkGeneric 12/2020 - 03/2006
12	carfilzomibIBA 03/2022 - 10/2013
10	Proteasome InhibitorsIBA 09/2020 - 07/2007
8	pomalidomideIBA 01/2022 - 10/2013
8	Monoclonal AntibodiesIBA 01/2022 - 08/2014
7	isatuximabIBA 01/2022 - 01/2019
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 10/2013
7	Immunomodulating AgentsIBA 12/2020 - 10/2013
6	Pharmaceutical PreparationsIBA 09/2020 - 09/2012
4	Alkylating AgentsIBA 09/2020 - 07/2007
3	elotuzumabIBA 10/2022 - 01/2021
3	daratumumabIBA 01/2022 - 01/2019
3	melflufenIBA 01/2021 - 05/2020
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2015 - 03/2011
3	Enoxaparin (Lovenox)FDA LinkGeneric 01/2012 - 03/2006
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2012 - 10/2007
2	ixazomibIBA 12/2021 - 12/2020
2	AntigensIBA 11/2020 - 01/2019
2	Zoledronic Acid (Zometa)FDA Link 10/2015 - 10/2008
2	Hemoglobins (Hemoglobin)IBA 10/2015 - 08/2007
2	defibrotideIBA 03/2012 - 07/2010
2	liposomal doxorubicin (Doxil)FDA Link 08/2010 - 04/2007
1	Bispecific AntibodiesIBA 11/2020
1	Immunoconjugates (Immunoconjugate)IBA 11/2020
1	Peptide Hydrolases (Proteases)FDA Link 09/2020
1	AminopeptidasesIBA 09/2020
1	Peptides (Polypeptides)IBA 09/2020
1	GoldIBA 09/2020
1	thiamine triphosphorate (TTP)IBA 01/2020
1	SteroidsIBA 01/2020
1	felzartamabIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	CytokinesIBA 01/2019
1	PanobinostatIBA 01/2018
1	AnthracyclinesIBA 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2017
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017
1	Histone Deacetylase InhibitorsIBA 01/2017
1	Pamidronate (Aredia)FDA LinkGeneric 10/2015
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2015
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2015
1	Proteins (Proteins, Gene)FDA Link 10/2014
1	cyclopentenyl cytosineIBA 07/2014
1	Warfarin (Coumadin)FDA LinkGeneric 03/2011
1	Drug CombinationsIBA 12/2010
1	C-Reactive ProteinIBA 08/2007
1	Indicators and Reagents (Reagents)IBA 08/2007
1	CreatinineIBA 08/2007
1	Immunoglobulin A (IgA)IBA 08/2007

Therapy/Procedure

29	Therapeutics 04/2021 - 08/2002
9	Stem Cell Transplantation 12/2020 - 08/2007
6	Salvage Therapy 03/2022 - 08/2007
3	Drug Therapy (Chemotherapy) 10/2018 - 08/2002
1	Immunotherapy 11/2020
1	Cardiopulmonary Resuscitation (CPR) 03/2016
1	Drug Tapering 06/2014
1	Transplantation 03/2014
1	Duration of Therapy 03/2014
1	VMP regimen 07/2011
1	Autologous Transplantation 02/2010
1	Homologous Transplantation 03/2007
1	Investigational Therapies (Experimental Therapy) 12/2006